These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32256805)

  • 1. Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma.
    Furubayashi N; Negishi T; Takamatsu D; Ieiri K; Inoue T; Tsukino K; Nakamura M
    Oncol Lett; 2020 Apr; 19(4):2943-2949. PubMed ID: 32256805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.
    Locke JA; Pond GR; Sonpavde G; Necchi A; Giannatempo P; Paluri RK; Niegisch G; Albers P; Buonerba C; Di Lorenzo G; Vaishampayan UN; North SA; Agarwal N; Hussain SA; Pal S; Eigl BJ
    Clin Genitourin Cancer; 2016 Aug; 14(4):331-40. PubMed ID: 26589729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy.
    Furubayashi N; Negishi T; Yamashita T; Kusano S; Taguchi K; Shimokawa M; Nakamura M
    Mol Clin Oncol; 2017 Dec; 7(6):1112-1118. PubMed ID: 29285384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder.
    Hsieh MC; Huang CH; Chiang PH; Chen YY; Tang Y; Su YL
    J Cancer; 2016; 7(10):1347-52. PubMed ID: 27390610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design.
    Necchi A; Giannatempo P; Lo Vullo S; Farè E; Raggi D; Nicolai N; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Feb; 13(1):80-86.e1. PubMed ID: 25027186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
    Furubayashi N; Morokuma F; Tomoda T; Hori Y; Negishi T; Miura A; Komori H; Kuroiwa K; Nakamura M
    Anticancer Res; 2022 Mar; 42(3):1571-1577. PubMed ID: 35220254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy.
    Mimura Y; Naiki T; Sugiyama Y; Tasaki Y; Odagiri K; Etani T; Nagai T; Iida M; Kimura Y; Ito N; Hotta Y; Yasui T; Furukawa-Hibi Y
    Cancer Diagn Progn; 2024; 4(4):475-481. PubMed ID: 38962546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma.
    Hsieh MC; Sung MT; Chiang PH; Huang CH; Tang Y; Su YL
    PLoS One; 2015; 10(6):e0129268. PubMed ID: 26114748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of relative dose intensity in gemcitabine-cisplatin chemotherapy for metastatic urothelial carcinoma.
    Kohei N; Sugiyama K; Chihara I; Muro Y; Imamura M; Nishio Y; Yoshimura K
    SAGE Open Med; 2018; 6():2050312118783011. PubMed ID: 30013781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
    Abe T; Ishizaki J; Kikuchi H; Minami K; Matsumoto R; Harabayashi T; Sazawa A; Mochizuki T; Chiba S; Akino T; Murakumo M; Miyajima N; Tsuchiya K; Maruyama S; Murai S; Shinohara N
    Urol Oncol; 2017 Feb; 35(2):38.e1-38.e8. PubMed ID: 27693091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.
    Nugent EK; Case AS; Hoff JT; Zighelboim I; DeWitt LL; Trinkhaus K; Mutch DG; Thaker PH; Massad LS; Rader JS
    Gynecol Oncol; 2010 Mar; 116(3):438-41. PubMed ID: 19896180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis.
    Qu HC; Huang Y; Mu ZY; Lv H; Xie QP; Wang K; Hu B
    Front Pharmacol; 2019; 10():1507. PubMed ID: 32009946
    [No Abstract]   [Full Text] [Related]  

  • 19. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
    Giannatempo P; Alessi A; Miceli R; Raggi D; Farè E; Nicolai N; Serafini G; Padovano B; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Gianni AM; Sonpavde G; Salvioni R; Necchi A; Crippa F
    Clin Genitourin Cancer; 2014 Dec; 12(6):433-9. PubMed ID: 24787972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.